Kadmon (KDMN) vs. Synlogic (NASDAQ:SYBX) Head-To-Head Survey

Kadmon (NYSE: KDMN) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Risk and Volatility

Kadmon has a beta of 5.39, suggesting that its stock price is 439% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.

Insider and Institutional Ownership

51.9% of Kadmon shares are owned by institutional investors. Comparatively, 64.2% of Synlogic shares are owned by institutional investors. 8.4% of Kadmon shares are owned by insiders. Comparatively, 18.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Kadmon and Synlogic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon -555.91% N/A -124.91%
Synlogic N/A -50.19% -46.76%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kadmon and Synlogic, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon 1 1 2 0 2.25
Synlogic 0 1 3 0 2.75

Kadmon presently has a consensus target price of $9.75, suggesting a potential upside of 89.69%. Synlogic has a consensus target price of $18.75, suggesting a potential upside of 91.33%. Given Synlogic’s stronger consensus rating and higher possible upside, analysts clearly believe Synlogic is more favorable than Kadmon.

Earnings & Valuation

This table compares Kadmon and Synlogic’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kadmon $26.06 million 15.51 -$208.75 million ($1.75) -2.94
Synlogic N/A N/A -$26.26 million ($9.43) -1.04

Synlogic has lower revenue, but higher earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Summary

Synlogic beats Kadmon on 9 of the 13 factors compared between the two stocks.

About Kadmon

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

About Synlogic

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply